Janux Therapeutics (JANX) Non Operating Income (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Non Operating Income of $9.9 million for Q1 2026, down 13.5% year-over-year from $11.4 million in Q1 2025, and down 5.77% quarter-over-quarter from $10.5 million in Q4 2025.
Janux Therapeutics (JANX) Non Operating Income (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Non Operating Income for 7 consecutive years, with $9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 13.5% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $42.5 million (up 18.59% YoY), while the FY2025 annual figure was $44.0 million, up 47.53% from the prior year.
- Non Operating Income slipped to $9.9 million in Q1 2026 per JANX's latest filing, from $10.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $11.4 million in Q1 2025 and bottomed at $132000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $6.0 million across 5 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 2874.32% — and 2026, when it decreased 13.5%.
- Janux Therapeutics' Non Operating Income stood at $2.2 million in 2022, then soared by 98.96% to $4.4 million in 2023, then soared by 101.1% to $8.8 million in 2024, then grew by 18.73% to $10.5 million in 2025, then declined by 5.77% to $9.9 million in 2026.
- Business Quant data shows JANX's Non Operating Income at $9.9 million in Q1 2026, $10.5 million in Q4 2025, and $10.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 9.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.72 Mn |
| Mar 31, 2026 | 9.85 Mn |
| Dec 31, 2025 | 10.46 Mn |
| Sep 30, 2025 | 10.94 Mn |
| Jun 30, 2025 | 11.26 Mn |
| Mar 31, 2025 | 11.39 Mn |
| Dec 31, 2024 | 8.81 Mn |
| Sep 30, 2024 | 7.78 Mn |
| Jun 30, 2024 | 7.86 Mn |
| Mar 31, 2024 | 5.40 Mn |
| Dec 31, 2023 | 4.38 Mn |
| Sep 30, 2023 | 4.25 Mn |
| Jun 30, 2023 | 3.24 Mn |
| Mar 31, 2023 | 2.82 Mn |
| Dec 31, 2022 | 2.20 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 373,000.00 |
| Mar 31, 2022 | 132,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 137,000.00 |